Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor for HSC Mobilization in Sickle Cell Disease
NCT02989701Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in sickle cell disease (SCD). Primary endpoints: Dose-Limiting Toxicities and Apheresis Collection Yield. Started Jan 2017; status: completed.
02
Drugs
plerixafor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02989701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989701.